Skip to main content
PLOS One logoLink to PLOS One
. 2024 Mar 28;19(3):e0300135. doi: 10.1371/journal.pone.0300135

Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platform

Lijuan Zhou 1, Fei Cai 1, Yanjie Li 2, Xinxin Gao 2, Yuehua Wei 1, Anna Fedorova 1, Daniel Kirchhofer 1, Rami N Hannoush 3,*, Yingnan Zhang 1,*
Editor: Maria Gasset4
PMCID: PMC10977697  PMID: 38547109

Abstract

Peptides present an alternative modality to immunoglobulin domains or small molecules for developing therapeutics to either agonize or antagonize cellular pathways associated with diseases. However, peptides often suffer from poor chemical and physical stability, limiting their therapeutic potential. Disulfide-constrained peptides (DCP) are naturally occurring and possess numerous desirable properties, such as high stability, that qualify them as drug-like scaffolds for peptide therapeutics. DCPs contain loop regions protruding from the core of the molecule that are amenable to peptide engineering via direct evolution by use of phage display technology. In this study, we have established a robust platform for the discovery of peptide therapeutics using various DCPs as scaffolds. We created diverse libraries comprising seven different DCP scaffolds, resulting in an overall diversity of 2 x 1011. The effectiveness of this platform for functional hit discovery has been extensively evaluated, demonstrating a hit rate comparable to that of synthetic antibody libraries. By utilizing chemically synthesized and in vitro folded peptides derived from selections of phage displayed DCP libraries, we have successfully generated functional inhibitors targeting the HtrA1 protease. Through affinity maturation strategies, we have transformed initially weak binders against Notch2 with micromolar Kd values to high-affinity ligands in the nanomolar range. This process highlights a viable hit-to-lead progression. Overall, our platform holds significant potential to greatly enhance the discovery of peptide therapeutics.

Introduction

Many natural peptides have been identified as important regulators of biological functions, acting as hormones, ion channels and GPCR modulators, growth factors, and neurotransmitters. They are usually selective and high-affinity ligands that bind to cell surface receptors and induce intracellular signaling. Therefore, peptides are an attractive modality for developing therapeutics to either agonize or antagonize cellular pathways associated with disease [1]. However, peptides often exhibit poor chemical and physical stability and a short plasma circulating half-life, limiting their therapeutic potential [2]. To overcome some of these peptide-intrinsic shortcomings, we considered using naturally occurring and highly stable disulfide constrained peptides (DCPs) as frameworks coupled with display technology aimed at generating de novo binders of therapeutically relevant target proteins [3]. Notebly, DCP library strategies has been effectively employed using mRNA display with MCoTI-II as a scaffold [4]. In this study, we employed phage display across seven distinct scaffolds to extent the applicability of this approach.

An important class of DCPs, known as cystine knot peptides (CKP), are naturally found in various plants and animals, exhibiting diverse pharmacological activities [5]. CKPs typically consist of approximately 30–50 amino acids and contain six conserved cysteine residues, which form three disulfide bonds in a I-IV, II-V, III-VI arrangement. Two disulfide bonds form a macrocycle together with the backbone which is penetrated by the third disulfide, resulting in a distinctive knotted topology. It is precisely this disulfide bond-stabilized compact structure that imparts remarkable stability to CKPs, protecting them from thermal, proteolytic, and chemical degradation [6]. The amino acid sequences between the six conserved cysteine residues form multiple surface-exposed loops, which exhibit significant variability in sequence and length. Hence, these loops appear highly suitable for conducting molecular evolution experiments against novel target proteins, enabling the generation of peptides with desirable physicochemical properties [7].

Cyclotides are small cyclic peptides isolated from plants. They typically comprise the cystine knot topology in addition to a distinct head-to-tail cyclized peptide backbone. These collective attributes result in cyclotides exhibiting intrinsic drug-like physicochemical properties akin to non-backbone cyclized CKPs [8].

Other DCPs, which do not possess the cystine knot topology and may have fewer or more than three disulfide bonds, also exhibit exceptional stability and resistance to thermal, chemical, and enzymatic degradation. Examples of such peptides include potentides [9], theta defensin 1 [10], and SFTI-1 [11]. These constrained peptidic frameworks could also be valuable candidates for utilization as scaffolds in peptide engineering endeavors.

Phage display serves as a powerful tool for protein engineering through molecular evolution. Historically, phage display has achieved widespread success in antibody engineering, leading to the development of numerous biotherapeutics currently available on the market [12]. In contrast, although phage display has been employed in peptide engineering for drug discovery purposes for many years, the inherent challenges associated with peptides as therapeutic agents have limited the number of peptide therapeutics developed using the phage display technology. However, there are some notable examples, such as Ecallantide, a treatment for hereditary angioedema [13]; Romiplostim, for treating immune thrombocytopenic purpura, an autoimmune disease [14]; and Tanzeum (albiglutide), a GLP-1 receptor agonist for glycemic control in adults with type 2 diabetes [15]. The development of a robust phage display platform utilizing peptide scaffolds with appropriate pharmacological properties would be highly desirable for efficient discovery of peptide therapeutics. This study introduces strategies that utilize phage display as the primary platform for the direct evolution of peptides based on DCP scaffolds. The objective of this strategy was to identify high-affinity ligands targeting specific proteins of interest, with the ultimate goal of developing peptide therapeutics.

Results

Display of DCP scaffolds on M13 surface

Phage display with filament M13 phage utilizes the secretion pathway of E. Coli to translocate the DCPs fused to phage coat protein p8 or p3 to the periplasmic space, where the DCPs are folded. Initially, we selected one CKP scaffold, namely EETI-II [16], and two cyclotide scaffolds, MCoTI-II [17], and kalata B1 [18], to assess the feasibility of displaying DCPs on the surface of M13 phage. The DCPs, incorporating an N-terminal gD-tag for quantification of display levels, were fused at the C-terminal to the major M13 coat protein p8 or the C-terminal domain of minor coat protein p3 (Fig 1A). Moreover, as both EETI-II and MCoTI-II are potent trypsin inhibitors, we measured phage binding to trypsin-coated plates to verify the correct folding of these phage surface-displayed DCPs. For phage display of the cyclotides MCoTI-II and kalata B1, ring opening was necessary to enable fusion with the phage coat proteins, as detailed in the methods section.

Fig 1. Phage display of four DCPs, EETI-II, McoTI-II, KalataB1 and EET-mut.

Fig 1

A. Diagram of the DNA constructs for both p3 and p8 phage display, denoting Ptac promoter, secretion signal peptide (Sig), gD tag, DCP and M13 major coat protein p8 or C-term domain of minor coat protein p3 (p3C). The sequences for signal peptide and gD tag are listed. B. Display level on p3 based on detection of gD tag; C. Phage binding to Trypsin with DCP displayed on p3; D. Display level on p8 based on detection of gD tag; E. Phage binding to Trypsin with DCP displayed on p8.

All three DCPs, when fused to either p8 or p3, exhibited high levels of display, as demonstrated by low EC50 values derived from phage ELISA titration curve using plate-coated anti-gD antibody (Fig 1B and 1C). Additionally, phage displaying EETI-II and MCoTI-II showed binding signals to immobilized trypsin, confirming functional folding (Fig 1D and 1E). As anticipated, kalata B1 did not exhibit any binding signal against trypsin. In addition to the native scaffolds, we also tested the display of a mutant derived from the EETI-II scaffold (EETI-mut), incorporating four mutations (M7R:Q11R:G22R:P23G), to investigate the adaptability of the scaffolds. The display level on p3 for EETI-mut was similar to that of the parent (Fig 1B), while the display on p8 seemed to decrease slightly but still maintained a high level of display. By contrast, the binding of EETI-mut to trypsin was significantly disrupted by the mutations (Fig 1D and 1E), indicating the mutations interfere the binding of EETI-II to trypsin.

Construction of phage displayed DCP libraries

Having established that DCPs can be efficiently displayed on phage, we proceeded with seven naturally occurring DCP scaffolds, including EETI-II, AVR9, circulin-A, Conotoxin-MVIIA, Huwentoxin, charybdotoxin and cellulose binding domain (CBD) to construct libraries with diversity in surface-exposed loops as follows (Fig 2).

Fig 2. Sequence and structural representation of library designs for DCP scaffolds.

Fig 2

A. Sequence representation and loop denotation of library design for 7 DCP scaffolds. The loops are color-coded as: blue for loop1, brown for loop2, green for loop3 (or loop3_4) and gray for loop5. All loops’ residues are underlined. The ring break point for AVR9 is indicated with bold font. Randomized residues are represented by red font X, representing 19 amino acids excluding Cysteine and the subscripted number of X indicated the length of the randomized region. Structural representation for 6 scaffolds: B. EETI-II (1mro); C. Circulin-A (1bh4); D. Conontoxin_MVIIA (1mvi); E. Humentoxin (1qk6); F. Charybdotoxin (1crd); G. CBD (1cbh). PDB codes are in parenthesis following the name of the scaffold. Regions that had been randomized are colored red. Loops involved in randomization are labelled with red font. Disulfides are shown as yellow. No structure is available for AVR9.

EETI-II, is a CKP-comprising squash trypsin inhibitor from the seeds of Ecballium elaterium, which has been used as a library scaffold for different display methods, including yeast [19] and bacterial surface display [20], as well as mRNA display [21]. For mRNA display, only six residues in Loop 1 (Fig 2A) were randomized to generate a library with diversity of 1 x 107 peptides [21]. For both bacterial and yeast display methods the maximum library sizes are 107–108, which limits randomization to only one loop of EETI-II, either Loop 1, Loop 2 or Loop 5, per individual library. However, phage display can generate libraries with diversity of up to 1011, making it possible to simultaneously randomize two loops of EETI-II. Therefore, we designed three EETI-II based libraries in which two loops were randomized simultaneously as well as individually (Fig 2A and 2B). Library I included residue diversity as well as loop length (6, 8, 10 residues) of Loop 1; library II had diversity in Loop 5 residues, but retained the native loop length; library III had diversity in both Loop 1 (residues and length) and Loop 5 (residues only). Altogether, the three libraries contained 1 x 1011 unique members.

AVR9 [22] is a CKP from the fungus cladosporium fulvum. While the structure of this scaffold is currently unavailable, a homology model predicted by DGII [23] exists. According to this model, all loops restrained by disulfide bonds exhibit well-defined secondary structures and are crucial for proper folding, making them unsuitable for randomization. The predicted structure of AVR9 bears resemblance to cyclotide kalata B1 in terms of ring size and the close proximity of its N- and C-termini, which facilitates head-to-tail cyclization. To create a library resembling the cyclotide structure, we modified the design by breaking one loop of the ring (Arg13-Ala14) and fusing the new C-terminus of AVR9 to p8. This arrangement allowed us to synthetically connect the original N- and C-terminal residues that are in close proximity to form a continuous region suitable for randomization. We carried out hard randomization for this region, varying the length of the randomized segment between 6 to 16 residues (as detailed in Fig 2A). The resulting library size reached a theoretical diversity of 2 x 1010.

Additional DCPs included were Circulin A [24], a CKP containing cyclotide from the African plant chassalia parvifolia; conotoxin-MVIIA [25], a CKP from the marine cone snail conus magus, which acts as a highly selective voltage-gated calcium channel blocker (CaV2.2), and Huwentoxin [26], a CKP isolated from the Chinese bird spider Haplopelma schmidti venom, a nicotinic acetylcholine receptor blocker. Available NMR structures show that these three DCPs each possess a long protruding loop that appear flexible and may tolerate randomization. Therefore, we selected Loop 4 of Circulin A, Loop 2 of conotoxin MVIIA, and Loop 1 for Huwentoxin for hard randomization including loops of various lengths (Fig 2A and 2C–2E). The library sizes were about 2 x 1010 for each.

Charybdotoxin [27,28] is a CKP from scorpion toxin that acts as a potassium channel blocker. A phage-displayed library with four randomized residues in a β-turn of charybdotoxin-Loop 4 has been successfully used to identify weak binders of CD4 [28]. We recapitulated this library design (lib 1) and, in addition, constructed two more libraries by extending the randomization to cover more regions on the β-sheet (lib 2), or on the surface of the helix (lib 3) (Fig 2A and 2F). The total diversity of the three libraries combined was 8 x 1010.

C-terminal cellulose binding domain (CBD) of cellobiohydrolase I from the fungus Trichoderma reesei is a well-characterized DCP scaffold, comprising only two disulfide bonds, that can be used as a prototype for phage display. In previous studies, CBD libraries were constructed in which the relatively flat cellulose binding region of CBD [29], or mainly the CBD-Loop 4 (Fig 2A) were randomized [30], yielding binders with new properties and selectivity against different target proteins. We recapitulated these designs (Fig 2A and 2G) to generate phage-displayed libraries of much higher diversity (2 x 1010) as compared to previously published studies of 5.5 x 108 and ~4 x 107.

Together these libraries comprise a large variety of shape and topology. The libraries including EETI-II, conotoxin-MVIIA, Circulin-A, and Huwentoxin as scaffolds were focused on loop randomization. The libraries with CBD as scaffold were more focused on surface randomization, whereas the libraries with charybdotoxin were designed by randomization of particular regions on secondary structures. The total diversity of the ensemble is around 2 x 1011.

Performance of DCP libraries against diverse protein targets

To evaluate the performance of these DCP libraries, we chose a panel of 16 highly diverse proteins for panning trials (Table 1). These soluble proteins cover a wide mass range (11–100 kDa) and have no sequence or structural homology. We employed the DCP libraries listed in Table 1 and successfully retrieved positive hits for 15 out of 16 protein targets (Table 1, S1 Table). In order to capture low affinity binders in the primary panning of all the libraries, we took advantage of multi-valent display by fusing the DCPs to the M13 major coat protein p8 [31]. Positive hits were defined as clones with intact sequences containing all cysteines of their respective DCP scaffold, having spot phage ELISA signals above 0.3 and signal/noise ratios of more than 2. The performances of the DCP libraries varied significantly based on the particular target protein, with the EETI-II libraries being the most successful, yielding 242 unique clones that bound to 14 of 16 protein targets (87.5%). The second-best libraries were based on the CBD scaffold with a success rate of 11/16 protein targets (68.7%) and a total of 172 unique clones. By contrast, the Circulin A and Charybdotoxin libraries had the lowest hit rate of 1/16 protein targets (6.3%) and yielded only 15 and two unique sequences, respectively. The libraries of the scaffolds AVR9, conotoxin-MVIIA and Huwentoxin performed moderately well, with hit rates of 5/16 (31.2%), 5/16 (31.2%) and 3/16 (18.8%) protein targets, respectively, and the retrieved unique sequences ranged from 9–43. In conclusion, the overall success rate of our DCP library ensemble for 16 protein targets was 93.8%, which is comparable to that of phage-displayed synthetic antibody libraries [32].

Table 1. Total number of unique clones obtained from each DCP scaffold against target proteins.

EETI-II AVR9 Circulin-A Conontoxin-MVIIA Huwen-toxin Charybdo-toxin CBD
HGFA 6 1
HtrA1 6 18 15 6 1 4
ApoL1 47 1
R-spondin 2
Insulin
Her3-Fc 11 1 2 1
Lgr5ECD-Fc 26 2 18
Fz7CRD-Fc 7 1 1 11
PCSK9 20 12 28
PCSK9 ΔCRD 14 3 2
BamA-amphipol 1
CD28-Fc 16 4
CD16A 44 4 11
EpCAM 39 90
Notch2Long 8
Notch2NRR 9 9 5

Biochemical characterization of synthesized initial hits

Based on the positive phage ELISA signal, we selected a panel of 34 clones for chemical synthesis and in vitro folding to validate ligand target binding. This panel of synthetic peptides represent all seven scaffolds and they cover a wide range of ELISA signals (signal range 0.3–4.0 and signal/noise range 3.0–40). The peptides were generated by solid phase peptide synthesis and folded under oxidative conditions [33]. The formation of disulfide bonds in the final product was confirmed with liquid chromatography-mass spectrometry (LC-MS) (S1 File). Binding of the 24 out of 34 synthetic peptides against their respective protein targets were confirmed by surface plasmon resonance (SPR) measurement (Table 2). Representative binding kinetics of DCP from each of the seven scaffolds are shown in Fig 3A. The affinities for these initial hits are all weak, with Kd values in the micromolar range and with fast on- and off-rates.

Table 2. Affinity summary for selected positive hits.

34 clones with spot ELISA signal range in 0.3–4.0 and signal/noise (s/n) ratio between 3–40 were selected for synthesis and in vitro folding, and the Kd of synthetic peptides were measured by SPR with steady state fitting.

Target DCP name Sequence Kd(μM) SPR ELISA s/n ratio
  EETI GCPRILMRCKQDSDCLAGCVCGPNGFCG      
Notch2Long N2L-EET-63 GCEQSTWWAPCKQDSDCLAGCVCYQRWHCG n/d 3.9 30.8
Notch2Long N2L-EET-57 GCDQGHSSGWQKCKQDSDCLAGCVCWFRWHCG n/d 1.7 17.1
Notch2Long N2L-EET-83 GCEQSTWWAPCKQDSDCLAGCVCYLRWHCG n/d 3.9 30.8
Notch2Long N2L-EET-62 GCGQTTAWEPCKQDSDCLAGCVCFMRWHCG n/d 2.8 32.6
Notch2Long N2L-EET-03 GCGWTLWHCKQDSDCLAGCVCEPIWWCD 43.7 0.3 3.1
Notch2Long N2L-EET-36 GCEVVMERCKQDSDCLAGCVCWYWTSCG n/d 2.2 18.3
Notch2Long N2L-EET-28 GCKQFGNQWICKQDSDCLAGCVCGPNGFCG n/d 1.6 13.7
Notch2Long N2L-EET-29 GCGWTLAHCKQDSDCLAGCVCQPRWVCG 102.5 0.6 4.4
Notch2NRR N2N-EET-57 GCRPRWGGWHCKQDSDCLAGCVCGPNGFCG 132.1 3.8 30.9
Notch2NRR N2N-EET-33 GCQQRRWGGWQQCKQDSDCLAGCVCGPNGFCG 55.6 3.6 28.9
Notch2NRR N2N-EET-45 GCGQQRWGGWPLCKQDSDCLAGCVCGPNGFCG 55.9 3.5 14.9
Notch2NRR N2N-EET-63 GCMPRYGGWHCKQDSDCLAGCVCGPNGFCG 166.1 1.5 21.3
Notch2NRR N2N-EET-n3 GCRPRFKGWTCKQDSDCLAGCVCGPNGFCG 180.1 2.1 33.1
Notch2NRR N2N-EET-n13 GCGQKRMGGWQWCKQDSDCLAGCVCGPNGFCG 12.0 3.4 53.9
HtrA1 HtrA1_EET76 GCHRPWWQLWGLCKQDSDCLAGCVCGPNGFCG 9.5 1.0 13.7
  CirA WIPCISAALGCSCKNKVCYRNGIPCGESC      
HtrA1 HtrA1_CirA65 WIPCISAALGCSCKNKVCYIFSKHLCGESCV 2.7 2.2 33.9
HtrA1 HtrA1_CirA38 WIPCISAALGCSCKNKVCYFLYQICGESCV 2.5 2.1 31.9
  AVR9 AFDCLGQCGRCDFHKLQCVHGVGLDYCNSSCTR      
Notch2NRR N2N-AVR-n6 AFDCLGQCGRCDFHKLQCVWSNRHSPYCNSSCTR 0.8 3.3 39.3
Notch2NRR N2N-AVR-19 AFDCLGQCGRCDFHKLQCVPYSWTYKQYCNSSCTR 9.4 2.6 35.7
HtrA1 HtrA1_AVR61 AFDCLGQCGRCDFHKLQCVMVYFIHMTKPYCNSSCTR > 20 1.7 24.4
HtrA1 HtrA1_AVR62 AFDCLGQCGRCDFHKLQCVRQIVWRVINLSHYCNSSCTR > 15 1.6 19.5
  HwTx ACKGVFDACTPGKNECCPNRVCSDKHKWCKWKL      
CD28-Fc CD28_Hwtx1 ACKGVFDACTVFEVTDTGVLECCPNAVCSDKHKWCKWKL n/d 1.4 9.8
HtrA1 HtrA1_HwTx69 ACKGVFDACTWKNWRQSRSRECCPNAVCSDKHKWCKWKL 3.7 0.9 9.6
  CnTx ECKGKGAKCSRLMYDCCTGSCRSGKC      
PCSK9DCRD PCSK9_CnTx1 ECKGKGAKCSYYMGIDKGYVNYCCTGSCRSGKC 4.5 2.0 29.7
PCSK9DCRD PCSK9_CnTx2 ECKGKGAKCSFMTRQGVQTWCCTGSCRSGKC 2.8 1.7 25.9
HtrA1 HtrA1_CnTx83 ECKGKGAKCSIQWSVYPWKVCCTGSCRSGKC 6.4 1.1 16.1
Fz7CRD-Fc Fz7-Fc_CnTx1 ECKGKGAKCSEYWIPMVGWVCCTGSCRSGKC n/d 5.1 32.7
  CBD GPTQSHYGQCGGIGYSGPTVCASGTTCQVLNPYYSQCLPGAS      
PCSK9 PCSK9FL_CBD1 GPTQSNYGMCGGIGYSGPTVCASGTTCQVLYPTTSRCLPGAS n/d 1.1 17.7
PCSK9 PCSK9FL_CBD2 GPTQSKYGMCGGIGYSGPTVCASGTTCQVLDPYTSQCLPGAS 3.6 1.9 26.8
Her3-Fc Her3-Fc_CBD1 GPTQSWQGRCGGIGYSGPTVCASGTTCQVLTPYWSECLPGAS 27.0 1.7 20.2
HtrA1 HtrA1_CBDwt46 GPTQSHYGQCGGWGYTGWYQCASGTTCQGPRSRLSQCLPGAS n/d 2.6 25.9
HtrA1 HtrA1_CBDamy86 GPTQSFWGWCGGIGYVGGRYCSGTTCQRPDAHWSQCLPGAS 158.0 1.6 22.8
  ChTx template VSCTTSKECWSVCQRLHNTSKGGCQGSFCTCGP      
Her3-Fc Her3-Fc_ChTx1 VSCTTSKECWSVCQRLHNTSWGEQCVTKFCKCEE > 10 1.7 22.6
Her3-Fc Her3-Fc_ChTx2 VSCTTSKECWSVCQRLHNTSWLGSCMERFCKCVD 1.5 1.6 24.3

Fig 3. Biochemical characterization of synthetic DCPs.

Fig 3

A. Representative SPR sensor grams for seven DCP scaffolds. The binding kinetic traces are shown as black and the fitted curve shown as red line. B. Inhibition of HtrA1 enzyme activity by DCPs derived from different scaffolds. C. Inhibition of bovine Trypsin by HtrA1_EET76 vs EETI-II.

In addition to binding, DCPs can be active in function against biological relevant enzymes. HtrA1 is homotrimeric serine protease, which has been implicated in diseases, such as Alzheimer’s disease, osteoarthritis, cancer and age-related macular degeneration [34]. The HtrA1 monomer consists of an N-terminal IGFBP-like module and a Kazal-like module, a central trypsin fold protease domain and a C-terminal PDZ domain [35,36]. The library screen identified HtrA1-binding DCPs representing six different scaffolds (Table 2). Following synthesis of nine clones from these six different scaffolds, their inhibitory potential (Table 2) was assessed in an HtrA1 enzyme assay using the fluorescence-quenched synthetic substrate H2-OPT [35]. We found that ligands from three different scaffolds, AVR9, EETI-II and Circulin-A inhibited HtrA1 activity by more than 50% at a concentration of 20 μM (Fig 3B). The most potent inhibitors were AVR62 and the three Circulin-A-based ligands, showing more than 75% inhibition. Among the inhibitors, the Circulin-A scaffold was most strongly represented and the Circulin-A DCP activities were consistent with their binding affinities determined by SPR (Table 2). Therefore, despite having the lowest overall protein target hit rate, the Circulin-A library yielded the highest number of inhibitory HtrA1 ligands. EETI-II is known to be a potent trypsin inhibitor. We derived a HtrA1 inhibitor from the EETI-II scaffold. On testing HtrA1_EET76’s specificity to bovine trypsin, we observed complete trypsin inhibition at 1 μM EETI-II, contrasting with no inhibition by HtrA1_EET76 (Fig 3C).

Affinity maturation strategies exemplified by anti-Notch 2 ligands

As presented in Table 2, the majority of the hits identified through initial panning against naïve DCP libraries exhibited weak micromolar-range binding to their respective targets. However, for drug leads, it is generally essential to achieve high affinity binding with a Kd in the sub-nanomolar range. Such high-affinity binding can be accomplished through affinity maturation strategies. Therefore, the strongest Notch 2-binding DCP, N2L-EET03 (Kd 43.7 μM, Table 3, S1 File) was selected for directed evolution using a soft randomization strategy (Fig 4A). In this approach, each residue in a given scaffold region has a 50% probability of mutating to any of the possible 20 amino acids, and a 50% probability of remaining as the parental sequence. On the other hand, hard randomization involves a 100% likelihood of mutating any given residue to any of the 20 potential amino acids. We designed a library targeting Loop 1 and Loop 5 (loop designation shown in Fig 2A) simultaneously, which was displayed on the major coat protein p8 and subsequently subjected to panning against Notch 2. During the selection process, an extended washing step was implemented to select for binders with slower off-rates. In order to assess the structure-activity relationship (SAR) of the parent clone, we generated a heat map to evaluate the enrichment score (ES) by comparing the frequency of amino acids at specific positions before and after panning (see methods section). The ES heatmap for the N2L-EET03 soft-randomization libraries indicated a preference for the mutation of Trp7 to Arg in Loop 1 and Ile24 to Lys/Arg in Loop 5 (Fig 4B). From this selection campaign, we chose 11 hits for peptide synthesis, and the affinities of the produced DCP were assessed using SPR (S2 Table). The campaign resulted in the creation of the best second-generation binder, N2L.EET03.10, which demonstrated a 10-fold improvement in affinity with Kd value of 4.5 μM (Table 3). Subsequently, we carried out multiple attempts using different randomization strategies to further enhance the affinity; however, none of these efforts yielded any additional improvements.

Table 3. Affinity summary for clones generated by affinity maturation strategies.

Clones with spot ELISA signal range in 0.3–4.0 and signal/noise (s/n) ratio between 3–40 were selected for synthesis and in vitro folding, and the Kd of synthetic peptides were measured by SPR. The two parents’ sequences were bolded. The template sequence is shaded with gray.

DCP name Sequence Kd(μM) SPR ELISA s/n Ratio
EETI template GCPRILMRCKQDSDCLAGCVCGPNGFCG      
N2L.EET03 GCGWTLWHCKQDSDCLAGCVCEPIWWCG 43.7 0.4 3.1
N2L.EET03.10 GCGWTLRHCKQDSDCLAGCVCRPIWYCG 4.5 3.0 48.4
N2L.EET31 GCIKSHLWCKQDSDCLAGCVCEVWIQCG >100 0.1 0.4
N2L.EET31.32 GCIKSHLWCPSDERCLAGCVCEVWIQCG 0.5 3.7
N2L.EET31.43 GCIKSHLWCKQDSDCEAGCICEVWIQCG 0.7 5.1
N2L.EET31.43.30 GCIKSHLWCPHGGRCEAGCICEVWIQCG 2.2 10.7
N2L.EET31.43.75 GCIKSHLWCDPRKDCEAGCICEVWIQCG 0.41 2.1 10.3
N2L.EET31.43.24 GCIKSHLWCPKTSDCEAGCICEVWIQCG 3.5 2.1 10.5
N2L.EET31.43.35 GCIKSHLWCPPPRRCEAGCICEVWIQCG 2.1 11.6
N2L.EET31.43.18 GCIKSHLWCHPKLDCEAGCICEVWIQCG 2.1 10.2
N2L.EET31.43.78 GCIKSHLWCDPRVSCEAGCICEVWIQCG 1.9 10.3
N2L.EET31.43.88 GCIKSHLWCDPRKSCEAGCICEVWIQCG 1.9 10.2
N2L.EET31.43.73 GCVRSHLWCKQDSDCEAGCICEVWIKCG 2.3 11.0
N2L.EET31.43.64 GCIRSHVWCKQDSDCEAGCICEVWVKCG 2.0 8.8
N2L.EET31.43.43 GCIRSHVWCKQDSDCEAGCICEIWIQCG 3.5 2.0 10.2
N2L.EET31.32.13 GCIKSHLWCPRDSDCLAGCVCEVWIQCG 35 2.2 10.2
N2L.EET31.32.29 GCIKSHLWCPRHEKCLAGCVCEVWIRCG 2.0 9.3
N2L.EET31.32.70 GCIRSHLWCPPSASCLAGCVCEVWIQCG 1.0 1.9 7.3
N2L.EET31.32.33 GCIKSHLWCPRAEKCLAGCICEVWIQCG 1.9 9.3
N2L.EET31.32.48 GCIKSHLWCPGKERCLAGCICEIWIQCG 1.9 7.2
N2L.EET31.32.21 GCIKSHLWCPPSDYCLAGCVCEVWIQCG 1.8 9.1
N2L.EET31.32.80 GCIRSQLWCPSDERCLAGCVCEVWIKCG 2.1 7.6
N2L.EET31.32.85 GCVRSHVWCPSDERCLAGCVCEIWIRCG 2.0 4.3

Fig 4. Affinity maturation of N2L_EET03 with multivalency display.

Fig 4

A. Stepwise affinity-maturation strategy diagram; B. Enrichment Score (ES) heatmap after panning target protein against the soft randomization library of N2L_EET03 displayed on p8.

Subsequently, we selected another primary hit, N2L.EET31, for affinity maturation as outlined in Fig 5A with improved outcome. Despite displaying a weak ELISA signal, N2L.EET31 was identified as the most abundant sequence by NGS analysis (56.6% in round 4). Notably, its enrichment was evident as early as round 2 during the initial panning (Fig 5B). Furthermore, N2L.EET31 exhibited competition with N2L.EET03 in a phage competition ELISA (Fig 5C), suggesting identical or overlapping binding sites. Due to these observations, N2L.EET31 was selected as another candidate for affinity maturation. An NNK-walking experiment (described in the methods section) provided valuable information on the functional importance of individual loop residues. The enrichment score (ES) heatmap of NNK-walking revealed high conservation of Ile3, Ser5, Leu7, and Trp8 in Loop 1, as well as Glu22 and Ile25 in Loop 5 (Fig 5D). These residues are either crucial for binding or play a critical role in overall peptide folding. Additionally, the conservation of Asp14 in Loop 2 and other Loop 2 residues suggested that even though Loop 2 was not randomized in the initial panning, it may be involved in Notch 2 binding. Gly18 in Loop 3 exhibited high conservation, suggesting its structural importance rather than direct involvement in binding. Based on this information, we designed hard randomization libraries for Loop 2 and Loop 3_4 as part of the second generation of affinity maturation.

Fig 5. Affinity maturation of N2L_EET31 with multi- and mono-valency display.

Fig 5

A. Stepwise affinity-maturation strategy diagram; B. N2L_EET31, the top-ranking sequence, identified with NGS; C. N2L_EET03 peptide compete with N2L_EET31 displaying phage in competition phage ELISA; D. Enrichment Score (ES) heatmap after panning target protein against the NNK-walking libraries of N2L_EET31 displayed on p8.

A total of 58 unique positive clones were identified from the Loop 2 library, while the Loop 3_4 library yielded 82 unique positive clones. Notably, highly conserved Pro10 and Gly18 were observed in the Loop 2 and Loop 3, respectively (Fig 6A). From the second-generation binders, nine top candidates were further cloned in p3 phagemid for ELISA assay. Two representatives displaying positive ELISA signals on p3, namely N2L.EET31.32 and N2L.EET31.43, were selected as parents for the third generation of affinity maturation using libraries displayed on p3 (Fig 6B). In both cases, simultaneous soft-randomization of Loops 1 and 5 was performed. In addition to soft-randomization, N2L.EET31.32 underwent hard-randomization on all residues except the first position of Loop 2, while N2L.EET31.43 was hard-randomized in all residues of Loop 2. A total of 111 and 126 binders were identified for parents N2L.EET31.32 and N2L.EET31.43, respectively. Sequence logo visualization of N2L.EET31.43 (Fig 6C) confirmed the highly conserved residues observed during NNK-walking and second-generation affinity maturation.

Fig 6. Affinity maturation of N2L_EET31 with multi- and mono-valency display.

Fig 6

A. Sequence logo after panning against hard randomized libraries of L2 and L3_4 displayed on p8 based on N2L_EET31. B. Screen p8-displayed library derived positive clones on p3 display and identified a few positive clones with signal/noise ratio > 2; C. Sequence logo after panning against soft randomized libraries displayed on p3 based on EET31.43.

Notably, two residues significantly deviated from the parent sequences, Arg4 versus Lys in Loop 1 and Pro11 versus Lys in Loop 2. Such sequence divergence typically indicates that these mutations may contribute to affinity improvement. The majority of binders identified during this campaign exhibited enhanced ELISA signals compared to the parents, indicating significant improvements in affinity (Table 3). Out of the affinity maturation campaign with N2L.EET31, a total of five clones were selected for synthesis, and their Kd values were measured using SPR. Among these clones, N2L.EET31.43.75 emerged as the strongest binder, exhibiting a Kd value of 410 nM—a 250-fold improvement in affinity over the parent DCP.

Discussion

In this study, we first successfully displayed four DCP scaffolds on the M13 phage surface by utilizing both the major coat protein p8 and the minor coat protein p3. We then demonstrated the binding capabilities of two specific scaffolds, EETI-II and McoTI-II, to their native binding partner trypsin while being displayed on the p8 protein on the phage surface. This finding indicates that these scaffolds are able to retain their correct folding when presented on the phage surface. Kalata B1 is a CKP containing cyclotide. We displayed this cyclotide by breaking one ring and generated peptide with new N- and C-termini, so that it can be fused to phage coat proteins for surface display. The successful display of this cyclotide in the format of DCP opened up the possibility of including cyclotides as DCP scaffolds for library construction. These findings provide evidence for the feasibility of utilizing phage display as a valuable platform for constructing a diverse library of DCP variants for purpose of engineering new functionalities.

We subsequently selected seven DCP scaffolds (including EETI-II) to form the basis of our DCP library ensemble. The design of these libraries was primarily informed by previous reports and insights derived from available DCP structures regarding loop flexibility. However, this approach does not guarantee a reliable design that can maintain native scaffold folding and stability during sequence and loop length randomization. Determining the percentage of DCP library members that effectively fold after being displayed on phage is challenging. Nevertheless, even if only a small fraction of the total library members can achieve the correct fold, we would still have a diverse pool of candidates to select from, provided we attain a library with sufficiently high diversity. In this study, we have achieved a total library size of approximately 1011, which can withstand a loss of diversity up to two magnitudes due to incorrect folding. Consequently, we believe we would still obtain a reasonably effective library size in the order of 109. Ideally, if we could predict crucial residues within a scaffold that contribute to stability and spontaneous folding and design the libraries by excluding these residues from randomization, we could enhance the percentage of correctly folded members and increase the effective diversity of the resulting library. We anticipate that future library design could benefit from advancements in machine learning technology for protein structure prediction in this regard [37].

The DCP scaffolds we selected in this study were peptides with molecular weight of 3–4 kDa. In contrast to the large surface area available for protein-protein interactions (PPI), including antibody-antigen interactions, where affinities can easily reach the nanomolar range (Kd), peptide ligands usually target a much smaller PPI surface area. If the PPI surface area is shallow and flat, such interactions typically exhibit affinities in the micromolar range (Kd) [38] Previously, phage display peptide libraries on the major coat protein p8 were developed to capture low-affinity binders by leveraging the avidity effect resulting from multivalent display [31]. We therefore anticipated that initial DCP hits would most likely bind to their targets with low affinity. Hence, we also chose to construct our naïve libraries by displaying DCP on the major coat protein p8 to take advantage of the increased avidity effect. In fact, the majority of hits initially identified during primary panning exhibited affinities in the range of double- to triple- digit micromolar range Kd. If we were to use monovalent display with p3, we would most likely be unable to capture these low-affinity binders, resulting in a significant reduction in the libraries’ effectiveness.

There are several advantages to our current DCP library ensemble compared to previously reported DCP libraries [1921,29,30,39]. Firstly, we are able to construct a naïve library with significantly higher diversity, 1011 compared to a maximum of 107 previously reported. Secondly, we have incorporated multiple scaffolds into our library ensemble to enhance the diversity in terms of shape, conformation and secondary structures offered by different scaffolds. As a result, we have achieved a level of library effectiveness from primary panning comparable to that of a synthetic phage-displayed antibody library [32].

The selected positive clones, identified through the phage-displayed library, were produced using solid-phase peptide synthesis and in vitro folding [33]. We confirmed that the majority of the positive hits exhibited the expected binding to their target proteins (Table 2). Moreover, we conducted further investigations on the ligands for HtrA1 and identified a few leads that show potential for inhibiting the protease activity of HtrA1 (Fig 3B). These results demonstrate that the sequences of positive hits identified through phage display can successfully be translated into functional molecules through peptide synthesis, followed by in vitro folding. The effective production of DCPs through chemical synthesis allows for easy chemical modification and subsequent incorporation of unnatural amino acids during the lead optimization process to impart drug-like properties of the DCPs.

However, we occasionally observed a discrepancy in binding signals between DCPs displayed on the phage surface and those synthesized in vitro. As indicated in Table 2, out of the 34 peptides that exhibited strong binding signals in phage ELISA, only 71% of their synthetic counterparts showed binding to the target proteins, as demonstrated by SPR. This discrepancy suggests that certain DCPs may not fold in vitro in the same manner as they do on the phage surface, where the folding of DCPs takes place within the bacterial periplasmic space and is aided by the bacterial secretion machinery throughout the entire process.

Unlike screening with antibody libraries, which typically yield tight binders during primary panning, the primary hits generated from our DCP libraries are predominantly weak binders with Kd values in the micromolar range. In this study, we demonstrated the potential to significantly enhance the affinity of these primary hits through several rounds of affinity maturation campaigns, resulting in the acquisition of high-affinity binders. We presented two distinct examples showcasing affinity maturation strategies.

In the first case (Fig 4), we employed an affinity maturation approach centered around the most potent binder determined by initial ELISA signal ranking. Our strategy involved a step-wise process. Initially, we generated a soft-randomization libraries by displaying the peptides on the major coat protein p8. Subsequently, we would proceed using the best hit from the p8-display library as parent to construct a monovalently displayed soft-randomization libraries to increase the selection stringency. However, panning with p8-displayed library resulted in binders exhibiting only 10-fold improvement in affinity, achieving a Kd in single digit micromolar range. This presented a challenge for the next step as the ligand binding was undetectable in phage ELISA assay under monovalent display conditions with a Kd in micromolar range, rendering further affinity maturation difficult at this point. Consequently, progressing beyond the micromolar range proved unfeasible in this case. Nevertheless, this approach could prove successful if the primary hits or the second-generation hits had already attained nanomolar-range affinity, at which point the monovalent display became detectable in phage ELISA. An illustration of this potential lies in our discovery of potent agonists for the Wnt signaling, wherein the initial hit with a Kd value of 34 nM was improved to become a lead with a Kd value of 1 nM [40].

In the second example (Figs 5 and 6), we started with a phage clone exhibiting extremely low binding affinity, as indicated by a weak ELISA signal and undetectable SPR binding signal. This clone was identified through deep sequencing, which revealed significant enrichment across multiple rounds of bio panning (Fig 5B). Initially, we employed an NNK-walking strategy to gather SAR information for the primary hits. This provided valuable guidance for design of the next generation of affinity maturation libraries. Then, we evaluated a panel of clones from the second generation, displaying them on p3, and identified two clones exhibiting weak ELISA signals. Both clones were chosen as parents for the third-generation affinity maturation. The third round of selection yielded hundreds of binders, with the tightest binder possessing a Kd of 410 nM. By combining deep sequencing, SAR-based library design and monovalent display of libraries, we successfully progressed from primary panning hits with barely detectable affinity (Kd > 100 μM) to ligands with Kd values in the nanomolar range. The affinity improvement surpassed 250-fold over three generations of affinity maturation, illustrating the effectiveness of the step-wise evolution strategy.

In conclusion, we have established a robust platform with potential to identify peptide therapeutical if combined with proper strategy of affinity maturation using DCPs as scaffolds. The effectiveness of this platform has been thoroughly evaluated and turned out to be comparable to synthetic antibody libraries. We have successfully demonstrated the feasibility of affinity maturation transforming weak binders with micromolar Kd values into moderate-affinity ligands in the nanomolar range. However, the process of hit-to-lead for DCP would take much longer time than that for antibody drugs. DCPs possess numerous properties that qualify them as drug-like scaffolds for peptide therapeutics. Our platform, comprising libraries based on a range of DCP scaffolds, has the potential to significantly enhance peptide drug discovery efforts utilizing DCPs as scaffolds in general [40]. While our study focused on only seven scaffolds, it is important to note that there are hundreds of other DCP scaffolds in nature. These additional scaffolds hold potential for inclusion in the library ensemble, further enhancing the robustness of our platform [33].

Methods

Protein reagents

Proteins that were purchased commercially are listed in the following in format of protein name (vendor name, catalog number): Her3-Fc (R&D, 348-RB); Fz7CRD-Fc (R&D, 6178-FZ); Insulin (Sigma-Aldrich, I2643) and CD28-Fc (R&D, 342-CD-200). The following human and bacterial (BamA) proteins were produced in house (Genentech) are listed as following in format of protein name (construct, gene ID, expression system): HGF activator (HGFA) (V373-S655, 3083, Hi5 Baculovirus) [41]; HtrA1 (Q23-P480, 5654, Tni Baculovirus) [35]; ApoL1 (D61-L398, 8542, SF9 Baculovirus) [42]; human R-spondin (A32-Q243, 340419, CHO); Lgr5ECD-Fc (M1-W558, 8549, CHO); PCSK9 (M1-Q692, 255738, CHO) [43]; PCSK9ΔCRD (Q31-G452 = PCSK9 lacking the C-terminal Cys-rich domain CRD, 255738, Tni Baculovirus) [44]; BamA-amphipol (BamA protein encapsulated with biotinylated amphipol) (V418-W810, 944870, E. Coli.) [45]; CD16A (G17-Q208, 2214, CHO); hEpCAM (Q24-K265, 4072, CHO); Notch2Long (Notch2 EGF6-EGF12) (D219-E418, 4853, CHO); Notch2NRR (Notch2 NRR domain) (A1423-Q1677, 4853, CHO). Proteins expressed in Baculovirus and E. Coli. systems were reported previously as referenced. Protein fragments generated by CHO cells were expressed as secreted proteins fused to either Fc (Lgr5ECD-Fc) or His tags (human R-spondin, CD16A, hEpCAM, Notch2Long and Notch2NRR), were purified to >90% purity using affinity chromatography. His tags were subsequently removed via TEV cleavage and the final products were purified with gel-filtration chromatography. Upon purification the proteins, HtrA1, PCSK9FL and PCSK9ΔCRD were in vitro biotinylated via Lys conjugation using EZ-Link™ Sulfo-NHS-LC-Biotinylation Kit (ThermoFisher, Cat.21435). CD16A, EpCAM, Notch2Long and Notch2NRR were biotinylated via N-term Avi tag using Enzymatic Protein Biotinylation Kit (Sigma-Aldrich, Cat. CS0008).

Display of DCPs on M13 phage

Linear sequences of EETI-II (GCPRILMRCKQDSDCLAGCVCGPNGFCG), KalataB1 (GLPVCGETCVGGTCNTPGCTCSWPVCTRN), McoTI-II (SGSDGGVCPKILKKCRRDSDCPGACICRGNGYCG) and EETI-IImut (GCPRILKRCKRDSDCLAGCVCRGNGFCG) was displayed on the surface of M13 bacteriophage by modifying previously described phagemids pS2202d and pS2202b for p3 and p8 display, respectively [46] (S2 and S3 Files). Standard molecular biology techniques were used to replace the fragment of pS2202d encoding gD tag and Erbin PDZ domain with a DNA fragment encoding for these DCPs. E. Coli harboring the resulting phagemids were co-infected with M13-KO7 helper phage and cultures were grown in 30 mL 2YT medium supplemented with 50 μg/mL carbenicillin and 25 μg/mL kanamycin at 37°C for overnight. The propagated phage was purified according to the standard protocol [47] and re-suspended in 1ml PBT buffer (PBS, 0.5% BSA and 0.1% Tween 20), resulting in the production of phage particles that encapsulated phagemid pS2202d_DCP and displayed DCP. The display level was analyzed using phage ELISA described previously [47].

Library construction and sorting

The DCP libraries listed in Fig 2A were constructed following Kunkel mutagenesis method [48]. The oligos used for library construction are listed in S3 Table. Residues denoted with “X” were randomized with equimolar of 19 amino acids, except Cys, using trinucleotide oligos. The stop template is the single strand DNA of pS2202b or pS2202d with EETI-II sequence containing three stop codons in both regions of P3–R8 and P23–G25. Twelve libraries based on DCP scaffolds of EETI-II, AVR9, Circulin-A, Conotoxin-MVIIA, Huwentoxin, Charybdotoxin and CBD were constructed (Fig 2A), each containing ~2 x 1010 unique members.

The libraries were pooled into two separate bins: three libraries made from EETI-II scaffold were mixed together as one pool and the remaining nine libraries mixed together as the second pool. Two pools of the libraries were cycled through rounds of binding selection either with solution panning protocol [44] against biotinylated HtrA1, PCSK9FL, PCSK9dCRDTEV, BamA-amphipol, CD16A, EpCAM, Notch2Long and Notch2NRR; or plate sorting protocol [47] against HGFA, R-spondin, Insulin, ApoL1, Her3-Fc, Lgr5ECD-Fc, Fz7CRD-Fc and CD28-Fc. After four to five rounds of binding selection, individual phage clones were picked, propagated and purified, and was analyzed with phage ELISA. Positive clones were subjected to either Sanger DNA sequence analysis or next generation sequencing (NGS).

Phage ELISA

After four rounds of binding selection, individual phage clones were picked and inoculated into 450μl 2YT media containing 50μg/ml Carbenecilin and M13-KO7 helper phage in 96-well blocks, which were grown at 37°C overnight. The supernatant was analyzed with spot phage ELISA as follows: target proteins were captured to 384-well Maxisorp immunoplates either through direct coating or affinity tag on protein, phage supernatant diluted (1:3) with PBT buffer (PBS with 0.5% BSA and 0.05% Tween 20) was added to the wells. The plates were washed and bound phage was detected with anti-M13-HRP followed by TMB substrate. In these assays, phage binding to BSA was tested in parallel to assess background binding. S/N is calculated as the ration between signals for target proteins over BSA (background). S/N > 2 were considered positive. Positive clones were subjected to DNA sequence analysis.

Peptide synthesis and in vitro folding

DCPs were produced with solid phase peptide synthesis. Briefly, linear peptides were synthesized, purified and folded using either buffer 1 (0.1 M ammonium bicarbonate, pH 9.0, 2 mM reduced glutathione, 0.5 mM oxidized glutathione, 4% DMSO) or buffer 2 (0.1 M ammonium bicarbonate, pH 8.0, 1 mM reduced glutathione, 50% DMSO) at 0.5 mg/mL for 24 h at RT with shaking. The folded peptides were purified with a C18 reversed phase HPLC column.

The final products were confirmed with LC-MS [33]. Peptide content was calculated using amino acid analysis. Selected peptides were synthesized by CS Bio (Menlo Park, CA).

NNK-walking

A top hit (N2L.31) against target hNotch2 was identified from the initial panning using the EETI-II library. For each non-cysteine position, an oligomer was designed with a NNK codon for mutagenesis at corresponding peptide position. Total 28 NNK-walking oligomers were synthesized, each with a 15-nucleotides flanking regions that are complementary to the phagemid at both ends. Oligomers were pooled at equal molar ratio, then the pooled oligomer was used to construct NNK-walking library, using the standard Kunkel mutagenesis method [48]. This NNK-walking library was panned against biotinylated hNotch2 in solution using M-280 Streptavidin Dynabeads (Invitrogen 11205D) first, then followed by one round of solid-phase panning using Neutravidin-coated NUNC MaxiSorp strips (Thermo 95029140). Solution and solid-phase panning used 200 nM and 20 nM biotinylated hNotch2, respectively. Phage samples were kept at each step for NGS analysis later.

Affinity maturation

Based on NNK-walking results, one soft- and two hard-randomization libraries were designed for affinity maturation, targeting Loop 1 and Loop 5, and Loops 2, and 3 and 4, respectively. For soft randomization of Loops 1 and 5, doping codon, designated as a 70:10:10:10 mixture of nucleotide bases and the wild type base was in excess, was used for each amino acid position in the targeting region and this results in approximately 50% mutation rate at the amino acid level. For hard-randomization of Loops 2, and 3 and 4, a NNK codon was used for each targeting position. These three libraries were each panned against biotinylated Notch 2 with one round of solution panning using M-280 Streptavidin Dynabeads followed by three rounds of solid-phase panning using MaxiSorp strips coated with Neutravidin or Streptavidin, alternatively between rounds.

Top hits identified from the above affinity maturation effort were cloned into p3 phagemid for ELISA. Two ELISA positive ones, namely N2L.31.L2.32 and N2L.31.L34.43, were picked for further improvement. In each case, one soft- and one hard-randomization libraries were designed targeting loops 1 and 5 and loop 2, respectively, using strategies described above. For each library sorting, one round of solution panning using M-280 Streptavidin Dynabeads followed by four rounds of solid-phase panning using MaxiSorp strips coated with Neutravidin or Streptavidin, alternatively between rounds.

Next generation sequencing (NGS)

Phage samples were kept at each step, representing a fraction of libraries, elution and negative controls. These samples were subjects to NGS analysis using Illumina MiSeq system with MiSeq Reagent Kits v2. Sample preparation and sequencing was performed by following manufacture’s instruction. Briefly, two rounds of PCR were used to amplify each sample. The first PCR adds a unique index to each sample; while the second PCR adds universal overhangs at both ends for sequencing purpose. Secondary PCR products were pooled, column purified and then quantified by qPCR, which is performed using KAPA Library Quant kit (Illuimina KK4835). Finally, NGS sample was run on a MiSeq with the “Generate FASTQ” module.

Enrichment Score (ES) calculation and ES heatmap generation

The sequences before and after sorting were all in same length. The frequencies for each of 20 amino acids at each position were calculated as fraction of the total count. F1 is the fraction in sorted sample; F0 is the fraction in unsorted sample. The enrichment score (ES) for a specific amino acid at a specific position was calculated as following:

If F1 > F0, ES = (F1-F0)/(1-F0)

If F1 < F0, ES = (F1-F0)/F0

Therefore, -1 < ES < 1, with negative number indicates de-enrichment and positive number indicates enrichment.

A two-dimensional (2D)-matrix table of ES can be calculated by comparing NGS datasets before and after sorting with sequence position number in x-axis and 20 amino acids on y-axis. A heatmap was generated by excel based on the 2D-matrix table using gradient 3-color scale, with blue for -1, white for 0 and red for +1.

Surface plasma resonance (SPR)

All binding experiments were performed using a Biacore S200 instrument (GE Healthcare) at 25°C at a flow rate of 50 μL/min. The kinetics and affinity measurements were carried out using either single-cycle or multi-cycle kinetics (SCK or MCK), solvent corrected and referenced by subtracting the signal to the blank flow cell. Binding affinity and kinetic parameters (association and dissociation rate constants, and dissociation equilibrium constant) were calculated with the Biacore S200 Evaluation Software (version 1.1.1, Cytiva) using either a 1:1 binding model or a steady-state equilibrium model (according to the manufacturer’s instructions). Final kinetics, affinity and standard deviations were calculated based on at least three independent experiments, and the standard deviations were typically less than 10%.

The binding affinities of DCPs and HtrA1 FL were determined with 10 mM HEPES (8.0); 200mM NaCl; 0.25% (v/v) CHAPS; 5% (v/v) DMSO as running buffer. Binding of HtrA1_HwTx69, HtrA1_CnTx83, HtrA1_CirA65 were measured using Series S Sensor Chip SA (Cytiva) captured approximately 900 RUs of biotinylated HtrA1 FL. While the binding affinity of HtrA1_CnTx83 and HtrA1_CirA65 DCPs were analyzed using MCK in a two-fold dilution series starting from 5 μM or 10 μM final concentrations, HtrA1_HwTx69 were studied using MCK in a three-fold dilution series starting from 10 μM.

Her3-Fc Avi-tag (R&D) was captured at about 1200 and 3000 RU on Series S Sensor Chip SA (Cytiva). The SPR measurements were done in HBS-EP+ buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20) plus 1% v/v DMSO. The binding affinity of Her3_ChTx2 was analyzed using MCK in a two-fold dilution series starting from 20 μM while Her3_CBD1 was in a three-fold dilution series starting from 100 μM.

Biolytined hPCSK9 FL was captured at about 600 and 800 RU on Series S Sensor Chip SA (Cytiva). The binding affinity of hPCSK9 DCPs to hPCSK9 FL were analyzed using MCK in a three-fold dilution series starting from 10 μM or 50 μM in a running buffer (10 mM HEPES (pH7.4), 150mM NaCl, 0.05% v/v Tween20, 2% v/v DMSO) at a flow rate of 50 μL/min.

rhCD28_Fc (Asn19-Pro152, Cat#342-CD, R&D) were captured at approximately 500, 950 and 1500 RU on Sensor Chip Protein A. CD28-HwTx1 in HBS-EP+ buffer plus 1% v/v DMSO with a three-fold dilution series starting from 100 μM were analyzed. No binding signal was detected using SCK.

Fz7CRD-Fc (Cat# 6178-FZ, R&D) were captured at around 800 and 2000 RU on Sensor Chip Protein A. hFz7-CrTx1 in HBS-EP+ buffer plus 5% v/v DMSO with a three-fold dilution series starting from 100 μM were analyzed. No binding signal were detected using SCK.

Biotinylated N2L protein (D219–E418, made in-house) and NRR protein (A1423–Q1677, made in-house) were captured at around 500, 1000 and 1500 RU on Sensor Chip SA (Cytiva). Binding affinity of N2L and N2N DCPs with their respective protein was measured in the running buffer (50 mM Tris, pH8.0, 100 mM NaCl, 2 mg/mL PEG3350, 1 mg/mL CM dextran, 1 mg/mL BSA, 0.0025% Tween20) with 3-fold serial dilution starting from 100 μM of peptides.

HtrA1 and bovine trypsin enzyme assay

Human full-length HtrA1 (HtrA1 FL) was expressed in Trichoplusia ni cells and purified as described [35,49]. Enzyme assays with the fluorescence-quenched synthetic substrate Mca-IRRVSYSF(Dnp)KK (H2-OPT) [35,50] were carried out essentially as described (Eigenbrot 2012). DCP stock solutions in DMSO were diluted in 50 mM Tris-HCl, pH 8.0, 200 mM NaCl, 0.25% CHAPS (assay buffer) and incubated with HtrA1 in 96-well black optical bottom plates for 15 min at 37°C. A 10 mM stock solution of H2-OPT in DMSO was diluted with water, prewarmed at 37°C and then added to the DCP-enzyme mixtures. The final concentrations in the reaction mixtures were: 1 nM HtrA1, 20 μM DCP, 5 μM H2-OPT, 0.1% DMSO. Substrate cleavage was measured at 37°C on a SPECTRAmax M5 microplate reader (Molecular Devices) and the initial rates of cleavage determined. Bovine Trypsin (Sigma T1426) enzyme assays were carried out similar to the above, with buffer of 50mM Tris-HCL pH8.0, 100mM NaCl, 0.1% Triton X-100 with reaction mixture of 1nM Bovine Trypsin, 1 μM EETI-II or HtrA1_EET76, 0.4mM S2222, 0.05% DMSO. The enzyme activities were expressed as percent of control values (without DCP). The determined values represent the average ± S.D. of three independent experiments.

Supporting information

S1 Table. Sequences and associated ELISA results for 507 positive clones outlined in Table 1.

The sequences are grouped into spreadsheets with target protein as spreadsheet names. The scaffold sequences and names are in bold font.

(XLSX)

pone.0300135.s001.xlsx (55.6KB, xlsx)
S2 Table. Affinity summary for clones generated by affinity maturation of N2L.EET03.

(XLSX)

pone.0300135.s002.xlsx (9.4KB, xlsx)
S3 Table. List of oligos for constructing libraries.

(XLSX)

pone.0300135.s003.xlsx (10.4KB, xlsx)
S1 File. CoA (Certificate of Analysis) for all DCPs listed in Table 2, Table 3 and S2 Table.

A zip file contains 51 pdf files with filenames are the same as the “DCP name” listed in the tables.

(ZIP)

pone.0300135.s004.zip (18.7MB, zip)
S2 File. Full sequence of phagemid pS2202b for p8 display.

(TXT)

pone.0300135.s005.txt (8.6KB, txt)
S3 File. Full sequence of phagemid pS2202d for p3 display.

(TXT)

pone.0300135.s006.txt (9.5KB, txt)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Binz H.K., Amstutz P., and Pluckthun A., Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol, 2005. 23(10): p. 1257–68. doi: 10.1038/nbt1127 [DOI] [PubMed] [Google Scholar]
  • 2.Fosgerau K. and Hoffmann T., Peptide therapeutics: current status and future directions. Drug Discov Today, 2015. 20(1): p. 122–8. doi: 10.1016/j.drudis.2014.10.003 [DOI] [PubMed] [Google Scholar]
  • 3.Tyler T.J., Durek T., and Craik D.J., Native and Engineered Cyclic Disulfide-Rich Peptides as Drug Leads. Molecules, 2023. 28(7). doi: 10.3390/molecules28073189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Liu W., et al., An Ultrapotent and Selective Cyclic Peptide Inhibitor of Human beta-Factor XIIa in a Cyclotide Scaffold. J Am Chem Soc, 2021. 143(44): p. 18481–18489. [DOI] [PubMed] [Google Scholar]
  • 5.Li C.Y., et al., Cystine Knot Peptides with Tuneable Activity and Mechanism. Angew Chem Int Ed Engl, 2022. 61(19): p. e202200951. doi: 10.1002/anie.202200951 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Craik D.J., Daly N.L., and Waine C., The cystine knot motif in toxins and implications for drug design. Toxicon, 2001. 39(1): p. 43–60. doi: 10.1016/s0041-0101(00)00160-4 [DOI] [PubMed] [Google Scholar]
  • 7.Kintzing J.R. and Cochran J.R., Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles. Curr Opin Chem Biol, 2016. 34: p. 143–150. doi: 10.1016/j.cbpa.2016.08.022 [DOI] [PubMed] [Google Scholar]
  • 8.Craik D.J., et al., Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol, 1999. 294(5): p. 1327–36. doi: 10.1006/jmbi.1999.3383 [DOI] [PubMed] [Google Scholar]
  • 9.Shen Y., et al., Potentides: New Cysteine-Rich Peptides with Unusual Disulfide Connectivity from Potentilla anserina. Chembiochem, 2019. 20(15): p. 1995–2004. doi: 10.1002/cbic.201900127 [DOI] [PubMed] [Google Scholar]
  • 10.Klotman M.E. and Chang T.L., Defensins in innate antiviral immunity. Nat Rev Immunol, 2006. 6(6): p. 447–56. doi: 10.1038/nri1860 [DOI] [PubMed] [Google Scholar]
  • 11.Colgrave M.L., et al., Sunflower trypsin inhibitor-1, proteolytic studies on a trypsin inhibitor peptide and its analogs. Biopolymers, 2010. 94(5): p. 665–72. doi: 10.1002/bip.21415 [DOI] [PubMed] [Google Scholar]
  • 12.Nagano K. and Tsutsumi Y., Phage Display Technology as a Powerful Platform for Antibody Drug Discovery. Viruses, 2021. 13(2). doi: 10.3390/v13020178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lehmann A., Ecallantide (Dyax/Genzyme). Curr Opin Investig Drugs, 2006. 7(3): p. 282–90. [PubMed] [Google Scholar]
  • 14.Hamzeh-Mivehroud M., et al., Phage display as a technology delivering on the promise of peptide drug discovery. Drug Discov Today, 2013. 18(23–24): p. 1144–57. doi: 10.1016/j.drudis.2013.09.001 [DOI] [PubMed] [Google Scholar]
  • 15.Fala L., Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits, 2015. 8(Spec Feature): p. 126–30. [PMC free article] [PubMed] [Google Scholar]
  • 16.Heitz A., et al., 1H 2D NMR and distance geometry study of the folding of Ecballium elaterium trypsin inhibitor, a member of the squash inhibitors family. Biochemistry, 1989. 28(6): p. 2392–8. doi: 10.1021/bi00432a009 [DOI] [PubMed] [Google Scholar]
  • 17.Felizmenio-Quimio M.E., Daly N.L., and Craik D.J., Circular proteins in plants: solution structure of a novel macrocyclic trypsin inhibitor from Momordica cochinchinensis. J Biol Chem, 2001. 276(25): p. 22875–82. doi: 10.1074/jbc.M101666200 [DOI] [PubMed] [Google Scholar]
  • 18.Pallaghy P.K., et al., A common structural motif incorporating a cystine knot and a triple-stranded beta-sheet in toxic and inhibitory polypeptides. Protein Sci, 1994. 3(10): p. 1833–9. doi: 10.1002/pro.5560031022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kimura R.H., et al., Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins, 2009. 77(2): p. 359–69. doi: 10.1002/prot.22441 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Christmann A., et al., The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides. Protein Eng, 1999. 12(9): p. 797–806. doi: 10.1093/protein/12.9.797 [DOI] [PubMed] [Google Scholar]
  • 21.Baggio R., et al., Identification of epitope-like consensus motifs using mRNA display. J Mol Recognit, 2002. 15(3): p. 126–34. doi: 10.1002/jmr.567 [DOI] [PubMed] [Google Scholar]
  • 22.Van den Ackerveken G.F., Vossen P., and De Wit P.J., The AVR9 race-specific elicitor of Cladosporium fulvum is processed by endogenous and plant proteases. Plant Physiol, 1993. 103(1): p. 91–6. doi: 10.1104/pp.103.1.91 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Vervoort J., et al., The race-specific elicitor AVR9 of the tomato pathogen Cladosporium fulvum: a cystine knot protein. Sequence-specific 1H NMR assignments, secondary structure and global fold of the protein. FEBS Lett, 1997. 404(2–3): p. 153–8. doi: 10.1016/s0014-5793(97)00117-8 [DOI] [PubMed] [Google Scholar]
  • 24.Daly N.L., et al., Solution structure by NMR of circulin A: a macrocyclic knotted peptide having anti-HIV activity. J Mol Biol, 1999. 285(1): p. 333–45. doi: 10.1006/jmbi.1998.2276 [DOI] [PubMed] [Google Scholar]
  • 25.Nielsen K.J., et al., A consensus structure for omega-conotoxins with different selectivities for voltage-sensitive calcium channel subtypes: comparison of MVIIA, SVIB and SNX-202. J Mol Biol, 1996. 263(2): p. 297–310. doi: 10.1006/jmbi.1996.0576 [DOI] [PubMed] [Google Scholar]
  • 26.Qu Y., et al., Proton nuclear magnetic resonance studies on huwentoxin-I from the venom of the spider Selenocosmia huwena: 2. Three-dimensional structure in solution. J Protein Chem, 1997. 16(6): p. 565–74. doi: 10.1023/a:1026314722607 [DOI] [PubMed] [Google Scholar]
  • 27.Bontems F., et al., Analysis of side-chain organization on a refined model of charybdotoxin: structural and functional implications. Biochemistry, 1992. 31(34): p. 7756–64. doi: 10.1021/bi00149a003 [DOI] [PubMed] [Google Scholar]
  • 28.Li C., et al., Phage randomization in a charybdotoxin scaffold leads to CD4-mimetic recognition motifs that bind HIV-1 envelope through non-aromatic sequences. J Pept Res, 2001. 57(6): p. 507–18. doi: 10.1046/j.1397-002x.2001.00876.x [DOI] [PubMed] [Google Scholar]
  • 29.Smith G.P., et al., Small binding proteins selected from a combinatorial repertoire of knottins displayed on phage. J Mol Biol, 1998. 277(2): p. 317–32. doi: 10.1006/jmbi.1997.1621 [DOI] [PubMed] [Google Scholar]
  • 30.Lehtio J., Teeri T.T., and Nygren P.A., Alpha-amylase inhibitors selected from a combinatorial library of a cellulose binding domain scaffold. Proteins, 2000. 41(3): p. 316–22. doi: [DOI] [PubMed] [Google Scholar]
  • 31.Sidhu S.S., Weiss G.A., and Wells J.A., High copy display of large proteins on phage for functional selections. J Mol Biol, 2000. 296(2): p. 487–95. doi: 10.1006/jmbi.1999.3465 [DOI] [PubMed] [Google Scholar]
  • 32.Fellouse F.A., et al., High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol, 2007. 373(4): p. 924–40. doi: 10.1016/j.jmb.2007.08.005 [DOI] [PubMed] [Google Scholar]
  • 33.Gao X., et al., A disulfide constrained peptide (DCP) phage library platform to identify novel human plasma protein binders. doi: 10.1371/journal.pone.0299804 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Skorko-Glonek J., et al., HtrA protease family as therapeutic targets. Curr Pharm Des, 2013. 19(6): p. 977–1009. doi: 10.2174/1381612811319060003 [DOI] [PubMed] [Google Scholar]
  • 35.Eigenbrot C., et al., Structural and functional analysis of HtrA1 and its subdomains. Structure, 2012. 20(6): p. 1040–50. doi: 10.1016/j.str.2012.03.021 [DOI] [PubMed] [Google Scholar]
  • 36.Truebestein L., et al., Substrate-induced remodeling of the active site regulates human HTRA1 activity. Nat Struct Mol Biol, 2011. 18(3): p. 386–8. doi: 10.1038/nsmb.2013 [DOI] [PubMed] [Google Scholar]
  • 37.Jumper J., et al., Highly accurate protein structure prediction with AlphaFold. Nature, 2021. 596(7873): p. 583–589. doi: 10.1038/s41586-021-03819-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Day E.S., Cote S.M., and Whitty A., Binding efficiency of protein-protein complexes. Biochemistry, 2012. 51(45): p. 9124–36. doi: 10.1021/bi301039t [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kimura R.H., et al., Functional mutation of multiple solvent-exposed loops in the Ecballium elaterium trypsin inhibitor-II cystine knot miniprotein. PLoS One, 2011. 6(2): p. e16112. doi: 10.1371/journal.pone.0016112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hansen S., et al., Directed evolution identifies high-affinity cystine-knot peptide agonists and antagonists of Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A, 2022. 119(46): p. e2207327119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Shia S., et al., Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol, 2005. 346(5): p. 1335–49. doi: 10.1016/j.jmb.2004.12.048 [DOI] [PubMed] [Google Scholar]
  • 42.Gupta N., et al., Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes. J Am Soc Nephrol, 2020. 31(9): p. 2065–2082. doi: 10.1681/ASN.2019080830 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Zhang Y., et al., Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. Nat Struct Mol Biol, 2017. 24(10): p. 848–856. doi: 10.1038/nsmb.3453 [DOI] [PubMed] [Google Scholar]
  • 44.Zhang Y., et al., Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem, 2014. 289(2): p. 942–55. doi: 10.1074/jbc.M113.514067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Vij R., et al., A targeted boost-and-sort immunization strategy using Escherichia coli BamA identifies rare growth inhibitory antibodies. Sci Rep, 2018. 8(1): p. 7136. doi: 10.1038/s41598-018-25609-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Skelton N.J., et al., Origins of PDZ domain ligand specificity: structure determination and mutagenesis of the Erbin PDZ domain. J. Biol. Chem., 2003. 278: p. 7645–7654. [DOI] [PubMed] [Google Scholar]
  • 47.Tonikian R., et al., Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries. Nat Protoc, 2007. 2(6): p. 1368–86. doi: 10.1038/nprot.2007.151 [DOI] [PubMed] [Google Scholar]
  • 48.Kunkel T.A., Roberts J.D., and Zakour R.A., Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol, 1987. 154: p. 367–82. doi: 10.1016/0076-6879(87)54085-x [DOI] [PubMed] [Google Scholar]
  • 49.Gerhardy S., et al., Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration. Nat Commun, 2022. 13(1): p. 5222. doi: 10.1038/s41467-022-32760-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Martins L.M., et al., Binding specificity and regulation of the serine protease and PDZ domains of HtrA2/Omi. J Biol Chem, 2003. 278(49): p. 49417–27. doi: 10.1074/jbc.M308659200 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Maria Gasset

21 Nov 2023

PONE-D-23-32053Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platformPLOS ONE

Dear Dr. Zhang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that convincingly addresses all the points raised during the review process. Please submit your revised manuscript by Dec 29 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Maria Gasset, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Note from Emily Chenette, Editor in Chief of PLOS ONE, and Iain Hrynaszkiewicz, Director of Open Research Solutions at PLOS: Did you know that depositing data in a repository is associated with up to a 25% citation advantage (https://doi.org/10.1371/journal.pone.0230416)? If you’ve not already done so, consider depositing your raw data in a repository to ensure your work is read, appreciated and cited by the largest possible audience. You’ll also earn an Accessible Data icon on your published paper if you deposit your data in any participating repository (https://plos.org/open-science/open-data/#accessible-data).

3. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Zhou et al describe the design and application of a number of new phage display libraries based on 7 cysteine constrained peptide scaffolds. They screen these libraries against 16 representative proteins identifying a range of moderate strength peptide binders. Two selected peptides are further affinity matured, in one case resulting in a peptide that binds in the mid-nanomolar range – still relatively weak for a cyclic peptide binder, but approaching an affinity which could be useful as a starting hit. On the whole the manuscript is clearly written and the conclusions presented are fair and valid. However, no supplementary information has been included which means much of the data needs to be taken on trust. Raw data needs adding to an SI before publication. More detailed methods are also required. Other than that I believe the reported data is sound and I have no hesitation recommending its publication following some additional minor modifications which I list below:

- Pg 3 line 40-42: I don’t really understand this sentence. Where do the immunoglobin domains come in? These haven’t been mentioned previously

- similar library approaches have been applied with mRNA display e.g. Liu et al JACS 143 18481 2021 and this work should be mentioned and cited in the introduction.

- pg 5 line 92: what is a gD tag? More generally I think it would be helpful to have a figure illustrating the library design described in lines 92-98.

- pg 5 line 99-100: Fig 1 shows a series of ELISA curves and this sentence states that “high levels of display” were observed. How is this quantified? What is “high” relative to? Can this data be more robustly quantified?

Pg 5 line 102: State “confirming functional folding” however the signal seems much lower here for a given Phage OD (again it would be useful to have actual quantification of this). Can you comment on this? Is it because a large portion of the expressed peptide is not folded correctly?

Pg 13 lines 239-243: Two residues are highlighted based on screening as showing favourable substitutions. In the improved peptide a third substitution has also been made W22Y. Please elaborate further. Were more peptides synthesised and tested and the one currently presented in table 3 is just the best? If so, all of this data should be included.

Pg 18 line 322-323: I’m not sure about this comment. Many PPIs are much tighter than µM. Please provide a reference to back this up.

Pg 21 line 394-5: I think it is too strong a claim to say this is a robust platform for discovery of peptide “therapeutics”. Also be what measure is this platform comparable to synthetic antibody libraries? I would say that the peptides being isolated are somewhat weaker binders than things derived from antibody libraries.

Pg 23 line 442: method for phage ELISA should be included since it is used substantially in the main figures. Please also explain how the S/N is calculated

Pg 24 peptide synthesis: this method should be included since there are many variations and the folding is non standard. All LC-MS data should be included in the SI

Examples of data that should be included in SI:

- Please include all ELISA data. E.g. Pg 9 line 178-180

- Please include all peptide LC-MS

- Please include all primers used for e.g. library construction

- Please include full sequences for phage libraries

Reviewer #2: In this manuscript Zhang et al describe a phage display platform for discovery of peptide therapeutics using diverse disulfide-constrained peptides as scaffolds. The screening platform yielded functional hits against a range of protein targets including HtrA1 and Notch2. A thorough and cleverly designed affinity maturation strategy is also described, which enabled hit-to-lead optimisation of a Notch2 ligand, providing a nanomolar binder. The platform could be highly beneficial for discovering therapeutic peptides and thus this paper will be of interest to the peptide community. I am in favour of publication after the minor corrections listed below are addressed.

Minor Corrections

1. Can you comment on the specificity of any of your hits? For example, EETI-II is a known trypsin inhibitor. Do your EETI-II-based HtrA1 inhibitors also inhibit trypsin? As you are optimising for affinity, it would be good to know that you aren’t isolating promiscuous ligands.

2. I’m sure this will be fixed in the final manuscript, but I found several figures, in particular figure 2, difficult to read due to poor resolution. Please provide clearer figures.

3. Could you include a sentence in the manuscript describing hard and soft randomisation. I think this would be useful for readers not familiar with this concept.

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Scott Lovell

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Mar 28;19(3):e0300135. doi: 10.1371/journal.pone.0300135.r002

Author response to Decision Letter 0


23 Jan 2024

Dear Editor:

Thank you for your careful review of our manuscript titled “Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platform” (PONE-D-23-32053). We appreciated the positive feedbacks and comments from both reviewers and have revised our manuscript accordingly with tracked change. We added two figure panels per reviewer’s requests (Fig 1A and Fig 3C) and six files (S1-S6) for Supporting Information. The titles and the list for Supporting Information are added as a new page in main text after Figure Legend section.

Following are our responses to two reviewers point by point. The reviewers’ comments/questions are in bold font and our responses are in regular font:

Reviewer #1: Zhou et al describe the design and application of a number of new phage display libraries based on 7 cysteine constrained peptide scaffolds. They screen these libraries against 16 representative proteins identifying a range of moderate strength peptide binders. Two selected peptides are further affinity matured, in one case resulting in a peptide that binds in the mid-nanomolar range – still relatively weak for a cyclic peptide binder, but approaching an affinity which could be useful as a starting hit. On the whole the manuscript is clearly written and the conclusions presented are fair and valid. However, no supplementary information has been included which means much of the data needs to be taken on trust. Raw data needs adding to an SI before publication. More detailed methods are also required. Other than that I believe the reported data is sound and I have no hesitation recommending its publication following some additional minor modifications which I list below:

- Pg 3 line 40-42: I don’t really understand this sentence. Where do the immunoglobin domains come in? These haven’t been mentioned previously

Deleted “beyond immunoglobin domains”

- similar library approaches have been applied with mRNA display e.g. Liu et al JACS 143 18481 2021 and this work should be mentioned and cited in the introduction.

Add “peptide library approaches have been applied with mRNA display” at line 44 and the reference is included.

- pg 5 line 92: what is a gD tag? More generally I think it would be helpful to have a figure illustrating the library design described in lines 92-98.

A new panel Figure 1A is added in Figure 1 with diagram of the constructs for both p8 and p3 display and cited in line 97. The sequences for signal peptide and gD tag are also listed in the figure. The references to other Figure 1 panels are modified accordingly in line 103-116 and the legend for Figure1 was modified as well.

- pg 5 line 99-100: Fig 1 shows a series of ELISA curves and this sentence states that “high levels of display” were observed. How is this quantified? What is “high” relative to? Can this data be more robustly quantified?

The curves illustrate the binding signal between the anti-gD antibody and the gD tag on the phage surface, dependent on phage concentration. The EC50 value represents the phage concentration where 50% of maximum binding is achieved. A lower EC50 indicates higher levels of gD tag presentation on each phage particle, implying a higher "display level". This results in an inverse correlation between EC50 and "display level". However, due to limitations in accurately measuring phage concentration with OD268, the EC50 value is only semi-quantitative. For reference, an OD268 of 1 typically corresponds to a phage concentration of 5 x 1012 pfu/ml.

“as demonstrated by low EC50 Values from phage ELISA titration curve” were added in line 103 to clarify the data.

Pg 5 line 102: State “confirming functional folding” however the signal seems much lower here for a given Phage OD (again it would be useful to have actual quantification of this). Can you comment on this? Is it because a large portion of the expressed peptide is not folded correctly?

As explained in the above question, it’s very hard to accurately determine the exact number of ligands displayed on phage surface, therefore it’s impossible to quantify the fraction of correctly folded peptides displaying on phage.

The subdued ELISA signal seen for trypsin binding to the DCP ligand displayed on the phage, when compared to the anti-gD and gD tag, could be due to several factors. Firstly, as mentioned by the reviewer, a significant portion of the displayed peptide might not fold correctly. Secondly, the binding between plate-coated trypsin and the phage-displayed peptide might be weak. This could be attributed to the coating of trypsin on a Maxisorp plate potentially distorting the protein's conformation, leading to a weakened binding signal. This occurrence is not uncommon, especially with proteases exhibiting high plasticity. Therefore, the data presented here is more qualitative rather than quantitative.

Pg 13 lines 239-243: Two residues are highlighted based on screening as showing favourable substitutions. In the improved peptide a third substitution has also been made W22Y. Please elaborate further. Were more peptides synthesised and tested and the one currently presented in table 3 is just the best? If so, all of this data should be included.

In fact, additional peptides had been synthesized and the affinity evaluated. The best one is listed in the Table 3. The additional data are listed in supplement Table 2. Based on S2 Table, I24K/R does not improve the affinity. The favorable mutation on this position as indicated by ES heat map could attribute to better display level. In addition, based on this table, W/Y/F at Pos22 are equally tolerated for binding. W7R is the critical change to improve the affinity. We added a brief description on this set of data in line 260-263, where the S2 table is cited.

Pg 18 line 322-323: I’m not sure about this comment. Many PPIs are much tighter than µM. Please provide a reference to back this up.

Tight PPI usually involve pocket or grooves. For shallow and flat surfaces, according to the new reference added in line 346, PPI with area over ~500A2 is usually needed to achieve stable complex.

Pg 21 line 394-5: I think it is too strong a claim to say this is a robust platform for discovery of peptide “therapeutics”. Also be what measure is this platform comparable to synthetic antibody libraries? I would say that the peptides being isolated are somewhat weaker binders than things derived from antibody libraries.

In line 417-418, we have toned down the claim to “we have established a robust platform with potential to identify peptide therapeutical if combined with proper strategy of affinity maturation using DCPs as scaffolds.”

The measure of a library effectiveness is rather arbitrary. Fellouse et. al. (reference cited in the MS) used “hit rate” as a rough indicator. In this paper, they panned a naïve synthetic antibody library against a panel of random proteins and got binders for 12 out of 13 proteins, that is, with hit rate of over 90%. We did the similar arbitrary evaluation on our library against 16 random proteins and observed hit rate of >90% as well. The affinity for primary binder is not the major indicator of the effectiveness for a library. By combining proper strategy of affinity maturation, there’s high chance to obtain high affinity lead eventually. However, due to the primary hits are usually with low affinity, the process for affinity maturation would take much longer time comparing to hit-to-lead process with antibody drugs.

We changed “high-affinity” to “moderate-affinity” in line 421, and added “However, the process of hit-to-lead for DCP would take much longer time than that for antibody drugs“ in line 422-423 to emphasize this shortcoming.

Pg 23 line 442: method for phage ELISA should be included since it is used substantially in the main figures. Please also explain how the S/N is calculated

Phage ELISA method has been added in Method section Line 492 -502, where the calculation of S/N is explained.

Pg 24 peptide synthesis: this method should be included since there are many variations and the folding is non standard. All LC-MS data should be included in the SI

Peptide synthesis method had been added in Method section (Line 504 - 510). All LC-MS data is now added in Supporting Information as S4, which is a zip file containing 51 CoA as pdf files. CoA contains all detailed information, including LC-MS data for each synthesized peptide reported in Table 2, Table 3 and S2 Table in this manuscript.

Examples of data that should be included in SI:

- Please include all ELISA data. E.g. Pg 9 line 178-180

A master table that includes all sequences and corresponding ELISA results is now added to Supporting Information as an excel workbook with 16 spreadsheets corresponding to 16 targets. The table is cited as S1 table at line 179 in the main manuscript text.

After a careful proof-reading Table 1 in line with S1 Table, we realized an error in original Table 1. The total hits for CD16a from EETI-II library should be 44 instead of 57 in previous version. We have made the correction and also correct the number in text in Line 192 accordingly.

- Please include all peptide LC-MS

Certificates of Analysis (CoA) for 51 peptides reported in Table 2, Table 3 and S2 Table are added in Supporting Information as a zip file containing 51 pdf files with file name the same as the “DCP name” in the tables. This information was cited in the main text in line 212-213 and line 248 as “S4 CoA”.

- Please include all primers used for e.g. library construction

Primers used for library construction are listed in the S3 Table and is cited in line 476 of the main text.

- Please include full sequences for phage libraries

The full sequences of phagemids for p3 and p8 display, pS2202d and pS2202b, are included in Supporting Information as 2 gb files. They are cited in main text in line 464 as S5 and S6.

Reviewer #2: In this manuscript Zhang et al describe a phage display platform for discovery of peptide therapeutics usingdiverse disulfide-constrained peptides as scaffolds. The screening platform yielded functional hits against a range ofprotein targets including HtrA1 and Notch2. A thorough and cleverly designed affinity maturation strategy is alsodescribed, which enabled hit-to-lead optimisation of a Notch2 ligand, providing a nanomolar binder. The platform could behighly beneficial for discovering therapeutic peptides and thus this paper will be of interest to the peptide community. I amin favour of publication after the minor corrections listed below are addressed.

Minor Corrections

1. Can you comment on the specificity of any of your hits? For example, EETI-II is a known trypsin inhibitor. Do your EETI-II-based HtrA1 inhibitors also inhibit trypsin? As you are optimising for affinity, it would be good to know that you aren’t isolating promiscuous ligands.

We did evaluate the inhibition specificity of HtrA1_EET76 vs. EETI-II against bovine trypsin. The results are added as Fig 3C and is cited in the main text line 233-236. Figure legend for Figure 3 was modified accordingly. As expected, HtrA1_EET76 is a specific inhibitor to HtrA1 and does not inhibit trypsin, in contrasting to the parent scaffold EETI-II that can fully inhibit trypsin activity.

2. I’m sure this will be fixed in the final manuscript, but I found several figures, in particular figure 2, difficult to read due to poor resolution. Please provide clearer figures.

A new set of figures with higher resolution are re-submitted alone with the revision.

3. Could you include a sentence in the manuscript describing hard and soft randomisation. I think this would be useful for readers not familiar with this concept.

The explanation is added in line 249-252.

Yours truly,

Yingnan Zhang, Ph.D. and Rami N. Hannoush, Ph.D.

Attachment

Submitted filename: RespToRevLetter012424.docx

pone.0300135.s007.docx (21.8KB, docx)

Decision Letter 1

Maria Gasset

20 Feb 2024

PONE-D-23-32053R1Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platformPLOS ONE

Dear Dr. Zhang,

Thank you for submitting your revised manuscript to PLOS ONE. Before its formal acceptance, reviewer 1 indicated the need of a minor but relevant acclaration in the introduction. Please submit your revised manuscript by Apr 05 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Maria Gasset, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: On the whole I am happy that the authors have addressed mine and the other reviewers comments. However I disagree with one response:

Original reviewing comment: - similar library approaches have been applied with mRNA display e.g. Liu et al

JACS 143 18481 2021 and this work should be mentioned and cited in the

introduction.

Response: Add “peptide library approaches have been applied with mRNA display” at line 44 and

the reference is included.

Further comment: This sentence has been added before the comments on DCPs as if it refers only to general mRNA display screens. My point was rather that mRNA display has been used to create modified DCP peptides in a similar manner (using a cyclotide MCoTI-II scaffold) to the screens in this paper (as shown in the cited paper) and this is what I think should be made clear in the introduction.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Scott Lovell

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Mar 28;19(3):e0300135. doi: 10.1371/journal.pone.0300135.r004

Author response to Decision Letter 1


20 Feb 2024

Dear Editor:

Thank you for your careful review of our revised manuscript titled “Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platform” (PONE-D-23-32053R1). We appreciated the positive feedbacks and comments from both reviewers. Following are our response to one point raised by Reviewer1. The reviewer’s comment is in bold font and our response are in regular font:

Reviewer #1: On the whole I am happy that the authors have addressed mine and the other reviewers comments. However I disagree with one response:

Original reviewing comment: - similar library approaches have been applied with mRNA display e.g. Liu et al

JACS 143 18481 2021 and this work should be mentioned and cited in the

introduction.

Response: Add “peptide library approaches have been applied with mRNA display” at line 44 and

the reference is included.

Further comment: This sentence has been added before the comments on DCPs as if it refers only to general mRNA display screens. My point was rather that mRNA display has been used to create modified DCP peptides in a similar manner (using a cyclotide MCoTI-II scaffold) to the screens in this paper (as shown in the cited paper) and this is what I think should be made clear in the introduction.

We have modified the Introduction to clarify that mRNA display had been successfully applied to DCP library strategies and our phage display approach has extended the applicability of the strategy. From line 43-49, the new text is:

“To overcome some of these peptide-intrinsic shortcomings, we considered using naturally occurring and highly stable disulfide constrained peptides (DCPs) as frameworks coupled with display technology aimed at generating de novo binders of therapeutically relevant target proteins [3]. Notebly, DCP library strategies has been effectively employed using mRNA display with MCoTI-II as a scaffold [4]. In this study, we employed phage display across seven distinct scaffolds to extent the applicability of this approach. “

Yours truly,

Yingnan Zhang, Ph.D. and Rami N. Hannoush, Ph.D.

Attachment

Submitted filename: RespToRevLetter022124.docx

pone.0300135.s008.docx (18.4KB, docx)

Decision Letter 2

Maria Gasset

23 Feb 2024

Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platform

PONE-D-23-32053R2

Dear Dr. Yingnan Zhang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Maria Gasset, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Maria Gasset

12 Mar 2024

PONE-D-23-32053R2

PLOS ONE

Dear Dr. Zhang,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Maria Gasset

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Sequences and associated ELISA results for 507 positive clones outlined in Table 1.

    The sequences are grouped into spreadsheets with target protein as spreadsheet names. The scaffold sequences and names are in bold font.

    (XLSX)

    pone.0300135.s001.xlsx (55.6KB, xlsx)
    S2 Table. Affinity summary for clones generated by affinity maturation of N2L.EET03.

    (XLSX)

    pone.0300135.s002.xlsx (9.4KB, xlsx)
    S3 Table. List of oligos for constructing libraries.

    (XLSX)

    pone.0300135.s003.xlsx (10.4KB, xlsx)
    S1 File. CoA (Certificate of Analysis) for all DCPs listed in Table 2, Table 3 and S2 Table.

    A zip file contains 51 pdf files with filenames are the same as the “DCP name” listed in the tables.

    (ZIP)

    pone.0300135.s004.zip (18.7MB, zip)
    S2 File. Full sequence of phagemid pS2202b for p8 display.

    (TXT)

    pone.0300135.s005.txt (8.6KB, txt)
    S3 File. Full sequence of phagemid pS2202d for p3 display.

    (TXT)

    pone.0300135.s006.txt (9.5KB, txt)
    Attachment

    Submitted filename: RespToRevLetter012424.docx

    pone.0300135.s007.docx (21.8KB, docx)
    Attachment

    Submitted filename: RespToRevLetter022124.docx

    pone.0300135.s008.docx (18.4KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES